ReviewIndian heart journal
LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker.
Review in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between non-high-density lipoprotein cholesterol and type 2 diabetes: a systematic review and meta-analysis of cohort studies.Endocrine journal · 2025Pooled it
- The effect of sumac and cinnamon on lipid profile and quality of life in patients with acute myocardial infarction, type 2 diabetes, and overweight/obesity: study protocol for a randomized double-blind controlled trial.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Elevated ASGR1 as a Potential Diagnostic Biomarker for Coronary Artery Disease and Predictor of Adverse Outcomes in Hypertensive Patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- A blood-based metabolomics study of cardiovascular diseases in Swedish twins reveals apolipoprotein B biology as important for myocardial infarction.GeroScience · 2026Article
- Emerging importance of remnant cholesterol compared with low-density lipoprotein cholesterol in cardiovascular risk assessment.Scientific reports · 2025Article
- Exploring the relationship between NHHR and the degree of coronary artery stenosis in patients with acute coronary syndromes.BMC cardiovascular disorders · 2025Article
- Cardiovascular disease lipids and lipoproteins biomarker standardization.Critical reviews in clinical laboratory sciences · 2025Review
- NON-HDL-C MIGHT PREDICT MAJOR ADVERSE CARDIOVASCULAR EVENT OCCURRENCE IN STATIN-NAÏVE PATIENTS FOLLOWING FIRST-TIME MYOCARDIAL INFARCTION - A PRELIMINARY REPORT.Acta clinica Croatica · 2025Article
- Comparative Analysis of Biomarkers in CAD: Evaluating Homocysteine, Lipid HS-CRP, Apo A, and ADMA.Journal of pharmacy & bioallied sciences · 2025Article
- The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictor of all cause and cardiovascular mortality in United States adults with NAFLD: a prospective cohort study.BMC gastroenterology · 2025Article
- Appraising non-HDL-C, systolic pressure, and a nomogram-based diagnostic model as auxiliary biomarkers in confirming acute ischemic stroke and transient ischemic attack.Scientific reports · 2025Article
- The effects of transdermal estrogens combined with Medroxyprogesterone Acetate on cardiovascular disease risk factors in postmenopausal women: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2025Review
- Validation of Scoring Tool for the Lipid Profile Interpretation in Exercise Training: SLIEX.The Malaysian journal of medical sciences : MJMS · 2025Article
- Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease.Scientific reports · 2025Article
- Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk.Nutrients · 2025Review
- The predictive value of triglyceride-glucose index combined with non-high-density lipoprotein cholesterol in coronary heart disease.BMC cardiovascular disorders · 2025Article
- Non-high-density lipoprotein cholesterol predicts cardiovascular risk better than remnant cholesterol in patients with type 2 diabetes mellitus.Frontiers in cardiovascular medicine · 2025Article
- The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with early onset type 2 diabetes with NAFLD: a cross-sectional study in China.Frontiers in nutrition · 2025Article
- Coronary risk factor profiles according to different age categories in premature coronary artery disease patients who have undergone percutaneous coronary intervention.Scientific reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The traditional approach to the management of coronary artery disease (CAD) focuses mainly on low density lipoprotein cholesterol (LDL-C) which is often considered a crucial risk factor for the progression of atherosclerosis. Despite its extensive use in predicting CAD risk, it has become a sub-optimal marker owing to several limitations. Recently, non-high density lipoprotein cholesterol (non-HDL-C) and apolipoprotein-B (Apo-B) have been substantiated to be more reliable predictors of CAD risk. On the basis of available evidence, it is fair to say that non-HDL-C is a more realistic primary target of therapy and can be used for initial screening. In the current scenario, India being a developing country, the population would not be burdened with additional cost of Apo-B estimation as non-HDL-C can be estimated in the non-fasting state which makes it both patient and clinician friendly. Considering this fact, the aim of the present review article is to highlight the reliability and efficacy of non-HDL-Cholesterol and hence make recommendations to incorporate non-HDL-C in routine lipid panel for better assessment of CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.